ATE241376T1 - Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten - Google Patents

Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten

Info

Publication number: ATE241376T1
Authority: AT; Austria
Prior art keywords: combination; taxanes; analogues; derivatives; compositions containing
Prior art date: 1997-03-13

Application number

AT98909066T

Other languages

English (en)

Inventor

Teresa Barlozzari

Andreas Haupt

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-13

Filing date

1998-03-09

Publication date

2003-06-15

1998-03-09 Application filed by Basf Ag filed Critical Basf Ag

2003-06-15 Application granted granted Critical

2003-06-15 Publication of ATE241376T1 publication Critical patent/ATE241376T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
229940123237 Taxane Drugs 0.000 title 1
LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical class C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
229930012538 Paclitaxel Natural products 0.000 abstract 1
230000001093 anti-cancer Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960001592 paclitaxel Drugs 0.000 abstract 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
229940063683 taxotere Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT98909066T 1997-03-13 1998-03-09 Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten ATE241376T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/819,101 US6103698A (en)	1997-03-13	1997-03-13	Dolastatin-15 derivatives in combination with taxanes
PCT/US1998/004594 WO1998040092A1 (en)	1997-03-13	1998-03-09	Dolastatin-15 derivatives in combination with taxanes

Publications (1)

Publication Number	Publication Date
ATE241376T1 true ATE241376T1 (de)	2003-06-15

Family

ID=25227196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98909066T ATE241376T1 (de)	1997-03-13	1998-03-09	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten

Country Status (30)

Country	Link
US (2)	US6103698A (de)
EP (1)	EP0981358B1 (de)
JP (1)	JP2001514659A (de)
KR (1)	KR100555604B1 (de)
CN (1)	CN1157223C (de)
AT (1)	ATE241376T1 (de)
AU (1)	AU728027B2 (de)
BG (1)	BG64338B1 (de)
BR (1)	BR9808249A (de)
CA (1)	CA2282720C (de)
CO (1)	CO4940498A1 (de)
CZ (1)	CZ293905B6 (de)
DE (1)	DE69815100T2 (de)
DK (1)	DK0981358T3 (de)
ES (1)	ES2200317T3 (de)
HK (1)	HK1026851A1 (de)
HR (1)	HRP980125A2 (de)
HU (1)	HU228860B1 (de)
ID (1)	ID23900A (de)
IL (2)	IL131597A0 (de)
NO (1)	NO323894B1 (de)
NZ (1)	NZ337416A (de)
PL (1)	PL197834B1 (de)
PT (1)	PT981358E (de)
RU (1)	RU2218174C2 (de)
SK (1)	SK285133B6 (de)
TR (1)	TR199902244T2 (de)
TW (1)	TWI277426B (de)
WO (1)	WO1998040092A1 (de)
ZA (1)	ZA982093B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010009901A1 (en) *	1996-12-11	2001-07-26	Basf Aktiengesellschaft Germany	Antineoplastic peptides
JP4776843B2 (ja)	1999-10-01	2011-09-21	イムノゲンインコーポレーティッド	免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20040101511A1 (en) *	2000-11-08	2004-05-27	Young Aiping H	Combination preparation of a biological response modifier and an anticancer agent and uses thereof
US20050192443A1 (en) *	2000-11-08	2005-09-01	Lorus Therapeutics Inc.	Biological response modifier for the treatment of cancer
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
EP2024362A4 (de)	2006-05-16	2012-01-25	Pharmascience Inc	An die iap-bir-domäne bindende verbindungen
AR080154A1 (es)	2010-02-10	2012-03-14	Immunogen Inc	Anticuerpos cd20 y su utilizacion
SG10201501095WA (en)	2010-02-12	2015-04-29	Pharmascience Inc	Iap bir domain binding compounds
WO2021246471A1 (ja) *	2020-06-03	2021-12-09	中外製薬株式会社	高難度配列の効率的ペプチド縮合法
KR20240051956A (ko)	2021-09-03	2024-04-22	도레이 카부시키가이샤	암의 치료 및/또는 예방용 의약 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US5676978A (en)	1989-02-14	1997-10-14	Amira, Inc.	Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US4879278A (en) *	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5278324A (en) *	1990-08-28	1994-01-11	Virginia Tech Intellectual Properties, Inc.	Water soluble derivatives of taxol
MX9102128A (es)	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
KR0185440B1 (ko)	1991-08-09	1999-04-01	야마구찌 다까시	신규의 테트라 펩티트 유도체
US5227400A (en) *	1991-09-23	1993-07-13	Florida State University	Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) *	1991-09-23	1993-10-05	Florida State University	Certain substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) *	1992-02-13	1993-12-21	Bristol-Myers Squibb Company	Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) *	1992-03-13	1994-05-06	Rhone Poulenc Rorer Sa	Procede de preparation de derives du taxane.
US5831002A (en) *	1992-05-20	1998-11-03	Basf Aktiengesellschaft	Antitumor peptides
US5248796A (en) *	1992-06-18	1993-09-28	Bristol-Myers Squibb Company	Taxol derivatives
US5254580A (en) *	1993-01-19	1993-10-19	Bristol-Myers Squibb Company	7,8-cyclopropataxanes
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
RU2132334C1 (ru) *	1992-12-16	1999-06-27	Басф Акциенгезельшафт	Аналог долостатина
US5484612A (en) *	1993-09-22	1996-01-16	The Board Of Trustees Of The Leland Stanford Junior University	Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
CA2129282A1 (en)	1993-09-29	1995-03-30	George Weber	Method for the treatment of neoplastic disease utilizing taxol and tiazofurin
US5447936A (en) *	1993-12-22	1995-09-05	Bionumerik Pharmaceuticals, Inc.	Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5565478A (en) *	1994-03-14	1996-10-15	The United States Of America As Represented By The Department Of Health & Human Services	Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5494930A (en) *	1994-06-02	1996-02-27	Shimizu; Yuzuru	Caribenolide I
US5525613A (en) *	1994-06-16	1996-06-11	Entropin, Inc.	Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5504191A (en) *	1994-08-01	1996-04-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) *	1994-08-01	1996-06-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory peptide amides
US5543423A (en) *	1994-11-16	1996-08-06	Vertex Pharmaceuticals, Incorporated	Amino acid derivatives with improved multi-drug resistance activity
EP0793499B1 (de)	1994-12-15	2005-10-19	Baker Norton Pharmaceuticals, Inc.	Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung

1997
- 1997-03-13 US US08/819,101 patent/US6103698A/en not_active Expired - Lifetime
1998
- 1998-03-09 TR TR1999/02244T patent/TR199902244T2/xx unknown
- 1998-03-09 JP JP53967998A patent/JP2001514659A/ja active Pending
- 1998-03-09 ES ES98909066T patent/ES2200317T3/es not_active Expired - Lifetime
- 1998-03-09 RU RU99122032/14A patent/RU2218174C2/ru not_active IP Right Cessation
- 1998-03-09 ID IDW991020A patent/ID23900A/id unknown
- 1998-03-09 CZ CZ19993211A patent/CZ293905B6/cs not_active IP Right Cessation
- 1998-03-09 PT PT98909066T patent/PT981358E/pt unknown
- 1998-03-09 DE DE69815100T patent/DE69815100T2/de not_active Expired - Lifetime
- 1998-03-09 PL PL335579A patent/PL197834B1/pl unknown
- 1998-03-09 NZ NZ337416A patent/NZ337416A/en not_active IP Right Cessation
- 1998-03-09 AT AT98909066T patent/ATE241376T1/de active
- 1998-03-09 CA CA002282720A patent/CA2282720C/en not_active Expired - Fee Related
- 1998-03-09 BR BR9808249-3A patent/BR9808249A/pt not_active IP Right Cessation
- 1998-03-09 SK SK1251-99A patent/SK285133B6/sk not_active IP Right Cessation
- 1998-03-09 AU AU66945/98A patent/AU728027B2/en not_active Ceased
- 1998-03-09 HU HU0001381A patent/HU228860B1/hu not_active IP Right Cessation
- 1998-03-09 KR KR1019997008305A patent/KR100555604B1/ko not_active Expired - Fee Related
- 1998-03-09 IL IL13159798A patent/IL131597A0/xx active IP Right Grant
- 1998-03-09 WO PCT/US1998/004594 patent/WO1998040092A1/en active IP Right Grant
- 1998-03-09 CN CNB988033089A patent/CN1157223C/zh not_active Expired - Fee Related
- 1998-03-09 EP EP98909066A patent/EP0981358B1/de not_active Expired - Lifetime
- 1998-03-09 DK DK98909066T patent/DK0981358T3/da active
- 1998-03-10 HR HR08/819,101A patent/HRP980125A2/hr not_active Application Discontinuation
- 1998-03-12 ZA ZA9802093A patent/ZA982093B/xx unknown
- 1998-03-12 CO CO98013903A patent/CO4940498A1/es unknown
- 1998-03-13 TW TW087103777A patent/TWI277426B/zh not_active IP Right Cessation
1999
- 1999-08-26 IL IL131597A patent/IL131597A/en not_active IP Right Cessation
- 1999-09-10 NO NO19994408A patent/NO323894B1/no not_active IP Right Cessation
- 1999-09-13 BG BG103728A patent/BG64338B1/bg unknown
2000
- 2000-03-07 US US09/520,254 patent/US6632795B1/en not_active Expired - Fee Related
- 2000-09-26 HK HK00106074A patent/HK1026851A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL131597A0 (en)	2001-01-28
BG103728A (en)	2000-04-28
JP2001514659A (ja)	2001-09-11
NO994408D0 (no)	1999-09-10
DK0981358T3 (da)	2003-09-22
CN1252728A (zh)	2000-05-10
PT981358E (pt)	2003-09-30
CA2282720C (en)	2009-12-29
DE69815100D1 (de)	2003-07-03
KR100555604B1 (ko)	2006-03-03
TWI277426B (en)	2007-04-01
CZ293905B6 (cs)	2004-08-18
PL335579A1 (en)	2000-05-08
HUP0001381A2 (hu)	2000-10-28
KR20000076211A (ko)	2000-12-26
AU6694598A (en)	1998-09-29
ZA982093B (en)	1999-09-12
DE69815100T2 (de)	2004-02-05
HUP0001381A3 (en)	2001-12-28
NO323894B1 (no)	2007-07-16
EP0981358A1 (de)	2000-03-01
CO4940498A1 (es)	2000-07-24
TR199902244T2 (xx)	1999-12-21
WO1998040092A1 (en)	1998-09-17
SK125199A3 (en)	2000-08-14
IL131597A (en)	2006-06-11
ID23900A (id)	2000-05-25
ES2200317T3 (es)	2004-03-01
BR9808249A (pt)	2000-05-16
AU728027B2 (en)	2001-01-04
NO994408L (no)	1999-11-10
HK1026851A1 (en)	2000-12-29
CA2282720A1 (en)	1998-09-17
CN1157223C (zh)	2004-07-14
EP0981358B1 (de)	2003-05-28
US6103698A (en)	2000-08-15
RU2218174C2 (ru)	2003-12-10
NZ337416A (en)	2001-05-25
CZ321199A3 (cs)	2000-02-16
BG64338B1 (bg)	2004-10-29
HRP980125A2 (en)	1999-02-28
US6632795B1 (en)	2003-10-14
SK285133B6 (sk)	2006-07-07
PL197834B1 (pl)	2008-04-30
HU228860B1 (en)	2013-06-28

Publication	Publication Date	Title
MX9306924A (es)	1994-05-31	Composiciones antitumorales que contienen derivados de taxano.
ATE342054T1 (de)	2006-11-15	Verfahren und zusammansetzung zur behandlung von krebs
FI935821A0 (fi)	1993-12-23	Fosfonooximetylestrar av taxanderivat
RU94029662A (ru)	1996-07-10	Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
NZ245795A (en)	1999-05-28	The use of paclitaxel formulations with reduced haematologic toxicity to treat tumours
RS20080167A (en)	2009-07-15	Novel improved compositions for cancer therapy
WO2002058694A3 (en)	2003-12-04	Method of treating hematologic tumors and cancers using beta lapachone
HU9602942D0 (en)	1996-12-30	Taxane class derivative based pharmaceutical compositions
FI955424A0 (fi)	1995-11-10	Syklodekstriinien kanssa muodostettuja taksoli- ja taksoteeri- tai Taxus-uuteinkluusiokomplekseja ja niiden valmistus ja käyttö
ATE241376T1 (de)	2003-06-15	Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
CY1110449T1 (el)	2015-04-29	Συνδυασμος δοκεταξελης και φλαβοπιριδinολης
ATE554753T1 (de)	2012-05-15	2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
DE69430797D1 (de)	2002-07-18	C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
PL350331A1 (en)	2002-12-02	C10 carbamoyloxy substituted taxanes as antitumor agents
AR031104A1 (es)	2003-09-10	Composicion farmaceutica que comprende un carboxialquileter y un agente antihipertensivo, primera composicion para su uso con una segunda composicion que comprenden un agente antihipertensivo y un carboxialquileter respectivamente, equipo que comprende un carboxialquileter y un agente antihipertensi
EP0793499A4 (de)	2000-11-08	Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
SI1287854T1 (sl)	2006-08-31	Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
HUP0103247A2 (hu)	2003-07-28	C7 észter szubsztituált taxánok
CA2206567A1 (en)	1996-06-20	Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound

Legal Events

Date	Code	Title	Description
2003-12-15	UEP	Publication of translation of european patent specification	Ref document number: 0981358 Country of ref document: EP

Date

Code

Title

Description

2003-12-15

UEP

Publication of translation of european patent specification

Ref document number: 0981358

Country of ref document: EP